Melanoma patients monitored for Long-Term effects after experimental drug combo

NCT ID NCT06848088

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This study follows 48 people with advanced melanoma who previously received the experimental drugs fianlimab and cemiplimab in an earlier study. No new treatment is given; instead, researchers track their health, cancer status, and any late side effects over time. The goal is to understand the long-term safety and effectiveness of the drug combination.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

California Pacific Medical Center

San Francisco, California, 94115, United States
Cancer & Hematology Centers of Western Michigan

Grand Rapids, Michigan, 49546, United States
Henry Ford Hospital

Detroit, Michigan, 48202, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08901, United States
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
South Texas Oncology And Hematology

San Antonio, Texas, 78229, United States
St. Vincent's University Hospital

Dublin, D04 T6F4, Ireland
The Angeles Clinic and Research Institute - West Los Angeles Office

Los Angeles, California, 90025, United States
University of Colorado Anschutz Medical Campus

Aurora, Colorado, 80045, United States
University of Kansas Hospital

Westwood, Kansas, 66205, United States
Virginia Cancer Care Specialist, PC

Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.